Company intelligence / Profile preview

Vandria SA

Lausanne/Epalinges, Vaud, Switzerlandvandria.com ↗

Ownership: Private
Development stage: Other

Overview

Vandria has dosed the first subjects in a Phase 1 clinical trial of VNA‑318, an orally available small molecule mitophagy inducer targeting CNS disorders. Preclinical data show improved memory/cognition and disease-modifying effects in models of Alzheimer’s/Parkinson’s. The company holds composition-of-matter patents on its lead series.

Therapeutic areas: GastroenterologyMetabolic DisordersImmunologyEndocrinologyOncologyRare DiseasesNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

VNA-318

1 more asset in the full pipeline.

Request access →

Partnerships

Open to partnering with biotech/pharma companies for both the mitophagy pipeline and ferroptosis inhibitors; no major partnerships announced yet as of June 2025.

Beyond the preview

Go deeper on Vandria SA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vandria SA.

Explore the full profile